Eloralintide Product Information
Eloralintide is a next-generation amylin receptor agonist designed for advanced metabolic research. Amylin receptor agonists activate the amylin pathway, which influences satiety, gastric emptying, and nutrient handling in non-human test subjects. This differs from GLP-1, GIP, and glucagon receptor agonists, which act on separate metabolic signaling systems. GLP-1 agonists primarily modulate appetite and glucose dynamics, GIP agonists influence nutrient-driven insulin responses, and glucagon receptor agonists affect energy expenditure. Amylin agonists complement these pathways by providing a direct satiety-focused mechanism. Eloralintide features an extended half-life that supports once-weekly administration in non-human test subjects, maintaining stable plasma levels throughout research protocols. In controlled studies, test subjects exposed to Eloralintide show dose-dependent reductions in food intake and measurable alterations in metabolic markers, making it a valuable tool for examining long-duration satiety regulation. In head-to-head research comparisons with other amylin receptor agonists, Eloralintide demonstrates superior performance. Pramlintide, a short-acting analog, produces modest effects but requires frequent administration in test subjects. Cagrilintide, a long-acting amylin agonist, produces stronger appetite-related outcomes, yet Eloralintide often surpasses it in consistency and potency. Eloralintide has shown weight-related reductions in non-human models approaching 9 to 20 percent, while Cagrilintide typically produces approximately 10 to 12 percent reductions under similar study conditions. Eloralintide also complements multi-pathway compounds such as Semaglutide, Tirzepatide, and Retatrutide, which act through GLP-1, GIP, and glucagon pathways. Its amylin-specific actions provide a distinct and synergistic research avenue. Eloralintide vs Retatrutide One of the most common questions in metabolic and receptor-signaling research today is: Eloralintide vs Retatrutide — how do these compounds differ? While both compounds are frequently discussed within metabolic research circles, they act through fundamentally different biological pathways. Retatrutide is an investigational triple receptor agonist that targets GLP-1, GIP, and glucagon receptors. Researchers have studied this multi-pathway approach because of its ability to engage several metabolic signaling systems simultaneously. Eloralintide, by contrast, is an amylin receptor agonist. Rather than acting through incretin-related pathways, Eloralintide is designed to target amylin signaling, a biological pathway associated with satiety signaling, gastric emptying, and nutrient handling in research models. Because these compounds engage different receptor systems, researchers often evaluate them as distinct tools for studying metabolic signaling and receptor biology. Growing interest in multi-pathway metabolic research has also increased discussion surrounding how amylin receptor agonists may be studied alongside GLP-1-, GIP-, and glucagon-based compounds in research settings. For this reason, Eloralintide is frequently discussed alongside compounds such as Semaglutide, Tirzepatide, Retatrutide, Pramlintide, and Cagrilintide when examining amylin signaling, incretin biology, and next-generation metabolic research pathways. Overall, Eloralintide serves as a research peptide for investigating amylin receptor function, satiety signaling, gastric emptying, and metabolic signaling exclusively in non-human research settings. As scientific interest continues to expand around amylin receptor agonists and multi-pathway metabolic research, Eloralintide remains an important investigational compound for researchers studying these biological systems. Summary of Characteristics Property Details Chemical Sequence of Amino Acids {γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{(α-Me-Phe)}-Leu-Val-Arg-Ser-Ser-Asn-{(N-Me-Asn)}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Methylene bridge: Cys2-Cys7) CAS Number 2883634-40-8 Molecular Formula C201H319N49O65S2 Molecular Weight 4526.10 Other Known Titles LY 3841136, Eloralintide
